Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial
Novartis' Cosentyx (secukinumab) 150 mg received FDA approval for polymyalgia rheumatica in patients who cannot taper steroids. The approval follows a trial where 40.5% of patients on Cosentyx achieved sustained remission at one year, compared to 20.5% on placebo. Cosentyx is the first IL-17 blocking biologic approved for this condition, according to Novartis.
How this was made

The 30-second read
Why it matters
The approval expands the drug's addressable market and could boost Novartis' specialty drug revenue, while also prompting insurers to negotiate pricing under Medicare's upcoming negotiations.
Market read
First FDA approval for an IL‑17 therapy in PMR, offering a new revenue stream and potential stock catalyst for Novartis.
What to watch
Potential safety concerns (serious infections) and competition from existing IL‑6 blocker Kevzara could temper demand.
Background
Cosentyx is already approved for psoriasis, psoriatic arthritis and other indications; this is its 11th U.S. indication.
Ticker impact
FDA approved Novartis' Cosentyx (secukinumab) 150 mg for polymyalgia rheumatica, based on REPLENISH trial data.
likely upward pressure as investors price in additional revenue from PMR indication
First FDA approval for an IL‑17 blocker in PMR, doubling sustained remission versus placebo, adds a sizable new market to an already high‑priced specialty drug.
Market effects
Biotech sector may benefit from renewed interest in IL‑17 therapies and specialty drug pipelines.
U.S. specialty pharma stocks could see modest gains; European peers may feel competitive pressure.
Adds to global pipeline of biologics for inflammatory diseases, potentially influencing worldwide market sentiment on biotech approvals.
Counterpoint
High cost and modest remission rates may limit uptake; insurers could push back on pricing.
Key entities
- CompanyNovartis
Pharmaceutical company receiving FDA approval for Cosentyx in PMR.
- DrugCosentyx (secukinumab)
IL‑17A blocking biologic now approved for polymyalgia rheumatica.



